Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis of fruquintinib plus best supportive care (BSC) compared with placebo plus BSC in metastatic colorectal cancer (mCRC): Results from the FRESCO-2 trial

被引：1

作者：

Stintzing, Sebastian

Tabernero, Josep

Satoh, Taroh

Dasari, Arvind

Lonardi, Sara

Eng, Cathy

Garcia-Carbonero, Rocio

Elez, Elena

Yoshino, Takayuki

Sobrero, Alberto F.

Yao, James C.

Kasper, Stefan

Arnold, Dirk

Basic, Edin

Granold, Matthias

Petschulies, Marco

Wu, Liwen

Chen, Lucy

Yang, Zhao

Van Cutsem, Eric

机构：

[1] Charite Univ Med Berlin, Dept Hematol Oncol & Canc Immunol, Berlin, Germany

[2] Vall dHebron Hosp Campus, Vall dHebron Inst Oncol, Barcelona, Spain

[3] Osaka Univ, Grad Sch Med, Dept Gastroenterol Surg, Suita, Japan

[4] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX USA

[5] Veneto Inst Oncol IOV IRCCS, Med Oncol Unit 1, Padua, Italy

[6] Vanderbilt Ingram Canc Ctr, Dept Med, Div Hematol Oncol, Nashville, TN USA

[7] Hosp Univ 12 Octubre Imas12, UCM, Madrid, Spain

[8] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Japan

[9] Azienda Osped San Martino, Dept Med Oncol, Genoa, Italy

[10] Univ Hosp Essen, West German Canc Ctr, Dept Med Oncol, Essen, Germany

[11] AK Altona, Dept Oncol & Hematol, Asklepios Tumorzentrum Hamburg, Hamburg, Germany

[12] Takeda Pharm Vertrieb GmbH & Co KG, Berlin, Germany

[13] Takeda Dev Ctr Amer Inc TDCA, Lexington, MA USA

[14] HUTCHMED Int Inc, Florham Pk, NJ USA

[15] Univ Hosp Gasthuisberg Leuven, Gastroenterol Digest Oncol, Leuven, Belgium

[16] KULeuven, Leuven, Belgium

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期

关键词：

130-231; 261-492-3532-2370-7650-2700; 283-237-255; 261-492-3532-2370-12160; 281-5277-2560; 9; 3; 2; 2461; 1;

D O I：

10.1200/JCO.2024.42.3_suppl.116

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：116 / 116

页数：1

共 50 条

[41] Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO, a randomized, double-blind, phase 3 trial comparing fruquintinib versus placebo plus best supportive care in Chinese patients with metastatic colorectal cancer (mCRC).
Xu, Ruihua
Li, Jin
Bai, Yu-Xian
Deng, Yanhong
Yang, Lei
Zhong, Haijun
Chen, Zhendong
Pan, Hongming
Guo, Weijian
Shu, Yongqian
Yuan, Ying
Xu, Jianming
Shen, Lin
Wang, Ning
Wang, Xin
Chi, Haidong
Peng, Jack
Hua, Ye
Su, Weiguo
Qin, Shukui
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[42] Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis to assess the impact of treatment with camrelizumab plus rivoceranib (cam plus rivo) on quality of life vs sorafenib (sora) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study CARES-310
Moon, A.
Raphael, N.
Chan, S. L.
Kaseb, A. O.
Jang, S. H.
Meng, X.
Cheng, A-L.
Qin, S.
Vogel, A.
ANNALS OF ONCOLOGY, 2024, 35 : S663 - S663
[43] Quality-adjusted time without symptoms or toxicity (Q-TWiST) of trastuzumab deruxtecan (T-DXd) versus chemotherapy in patients with advanced gastric cancer from the DESTINY-Gastric01 trial.
Cella, David
Hackshaw, Michelle D.
Vondeling, Gerard T.
Bennett, Lee
Garbinsky, Diana
Saito, Kaku
Sugihara, Masahiro
Bang, Yung-Jue
Yamaguchi, Kensei
Shitara, Kohei
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[44] Quality Adjusted Time without Symptoms or Toxicities (Q-TWiST) of Ixabepilone (Ixa) Plus Capecitabine (Cape) Versus Capecitabine for Metastatic Breast Cancer (MBC) Patients with Poor Prognostic Features (PPF)
Orsini, L. S.
Mukhopadhyay, P.
Peck, R.
Corey-Lisle, P.
CANCER RESEARCH, 2009, 69 (24) : 782S - 782S
[45] A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of patients in CheckMate 649: Nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC)
Sugarman, Ryan
Botteman, Marc
Rusibamayila, Nifasha
Nguyen, Hiep
Lin, Daniel
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[46] Quality-adjusted time without symptoms of disease progression or toxicity of treatment (Q-TWiST) analysis to assess benefit-risk of sacituzumab govitecan (SG) in previously treated patients (pts) with metastatic triple-negative breast cancer (mTNBC)
Brufsky, A. M.
Bardia, A.
Sedrak, M. S.
Loibl, S.
Tolaney, S. M.
Punie, K.
Hurvitz, S. A.
Kalinsky, K.
Cortes, J.
O'Shaughnessy, J.
Dieras, V. C.
Piccart, M.
Dasgupta, A.
Kaushik, A. G.
Lai, C.
Shi, L.
Rugo, H. S.
ANNALS OF ONCOLOGY, 2024, 35 : S382 - S383
[47] Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML
Jorge E. Cortes
Tara L. Lin
Geoffrey L. Uy
Robert J. Ryan
Stefan Faderl
Jeffrey E. Lancet
Journal of Hematology & Oncology, 14
[48] Capecitabine 1best supportive care (BSC) or erlotinib plus BSC as overall survival (OS) benefit over BSC alone in unresectable/metastatic gall bladder cancer (GBC) patients with ECOG PS-III. Results from a phase II randomised controlled trial (RCT)
Kataria, B.
Sharma, A.
Mishra, S.
Bhatnagar, S.
Thulkar, S.
Yadav, M.
Sahoo, R. K.
Pramanik, R.
Prasad, C. P.
Sreenivas, V.
ANNALS OF ONCOLOGY, 2019, 30 : 279 - 279
[49] A Quality-adjusted Time Without Symptoms and Toxicity (Q-TWiST) analysis comparing nivolumab plus chemotherapy (N plus CT) or nivolumab plus ipilimumab (N plus I) vs CT in patients (pts) with tumor cell PD-L1 ≥ 1% advanced esophageal squamous cell carcinoma (ESCC): CheckMate 648
Chau, I.
Bridgewater, J. A.
Wyrwicz, L. S.
Greenwood, M.
Blum, S. I.
Moreno-Koehler, A.
Martin, E.
Taylor, F.
Davis, C.
Singh, P.
ANNALS OF ONCOLOGY, 2024, 35 : S162 - S162
[50] Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7+3 in older adults with newly diagnosed high-risk/secondary AML
Cortes, Jorge E.
Lin, Tara L.
Uy, Geoffrey L.
Ryan, Robert J.
Faderl, Stefan
Lancet, Jeffrey E.
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)

← 1 2 3 4 5 →